TP53 and Miyoshi myopathy: Importantly, the combination is effective in MM cells having a distinct genetic background and in particular, exhibiting either an abnormal or a wild-type TP53 status (e.g., H929 vs. L363 cell lines, Table S1); this is an important point since MM cells frequently exhibit an inactivation of the p53 pathway [35].